Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. (Q54520623)

30 May 2018

title

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. (English)

1 reference

30 May 2018

2

Kiat Ruxrungtham

1 reference

30 May 2018

3

Constance Delaugerre

1 reference

30 May 2018

author name string

Hai Le Nguyen

series ordinal

1

1 reference

30 May 2018

publication date

23 March 2012

1 reference

30 May 2018

published in

Intervirology

1 reference

30 May 2018

volume

55

1 reference

30 May 2018

issue

4

1 reference

30 May 2018

page(s)

287-295

1 reference

30 May 2018

HIV-1 integrase inhibitor resistance and its clinical implications

cites work

1 reference

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

21 January 2018

1 reference

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs

21 January 2018

1 reference

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications

21 January 2018

1 reference

The challenge of HIV-1 subtype diversity

21 January 2018

1 reference

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors

21 January 2018

1 reference

Short communication: retrospective study to time the introduction of HIV type 1 non-B subtypes in Lyon, France, using env genes obtained from primary infection samples

21 January 2018

1 reference

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection

21 January 2018

1 reference

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

21 January 2018

1 reference

Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.

21 January 2018

1 reference

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

21 January 2018

1 reference

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.

21 January 2018

1 reference

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

21 January 2018

1 reference

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000336658

1 reference

30 May 2018

1 reference

30 May 2018